Insulin resistance is inversely and independently associated with bone size in young men without diabetes, according to a new study.

Researchers say sleeping BP may be novel target for diabetes prevention.

CV data added to labels for treatments containing empagliflozin.

True or false? Diabetes increases the risk for conjunctivitis. Follow the link to see if you got it right!

Which new drug class have you seen the best results with in lowering A1c’s? 1) DPP-4 2) GLP-4 3) SGLT-2 4) Other Follow the link to see what others think!

Manage diabetes quickly and on the go with LogFrog DB Lite, free for seven days of use! In a few seconds you can track: blood glucose, insulin or oral medication, carb intake, exercise, weight and more! LogFrog DB Lite can help keep you organized and help you analyze and better understand your data.

When we think about disasters, we usually think of the outcome, a poor health outcome. We don’t always think about the journey. The journey to poor health outcomes are many. Today I am reminded of not having the insurance coverage for the correct medication. Without it, one can have a disaster, poor diabetes management. The consequences of that, as well as the disruption to running a smooth office.

In this week's Homerun Slides, the cardiovascular outcomes of patients in the placebo vs empagliflozin study.

Insulin receptors, ligand binding: The insulin action sequence is initiated with specific binding to high-affinity receptors on the plasma membrane of target cells. The insulin receptor is a large transmembrane glycoprotein consisting of two alpha- and two beta- subunits that form a heterotetramer, as depicted in Figure 12.1. The insulin receptor is synthesized from a single gene as a polypeptide pro receptor comprised of alpha- and beta- subunit sequences in tandem.

Recent survey finds support for keeping parts of it intact, even those who want it repealed.